3 AI Stocks Wall Street Expects to Return Up to 595% in 2024

By Trey Thoelcke Published Mar 28, 8:40AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

3 AI Stocks Wall Street Expects to Return Up to 595% in 2024 — © denphumi / iStock via Getty Images

Excitement over the prospects for artificial intelligence (AI) continues to be a significant driver for many stocks, including several of the so-called Magnificent Seven. The question for investors who have been wary about what might have been a fad, or those who are simply late to the party, is whether they have missed the boat. Have all the profits in AI stocks been made?

There may still be opportunities to be found. Take for example Exscientia PLC (NASDAQ: EXAI), Guardforce AI Co. Ltd. (NASDAQ: GFAI), and Microbot Medical Inc. (NASDAQ: MBOT). These AI stocks have retreated in the past year, and yet analysts anticipate strong rebounds for them in the next 12 months. So what’s up here? Let’s have a look.

Exscientia

An AI-driven pharmatech company.

This AI-driven pharmatech company engages in the application of AI and machine learning to the discovery and design of therapeutic compounds. Its platform enables it to design candidate drug molecules, as well as to provide patients with drug therapies through AI-guided assessment.

The stock briefly spiked in February after the company’s CEO was ousted for having inappropriate relationships with employees. But the company has posted disappointing quarterly and full-year results since then, and the share price is now down almost 10% year to date. Shares went public at $22 apiece, but they have traded for as high as $9.12 in the past year. Analysts don’t expect it to go that high in the next 12 months but still see plenty of room for it to run.

Past-Year Price Change	Target Price	Est. One-Year Gain
−8.2%	$8.67	51.0%

Note though that two of the three analysts who follow the stock rate it at Hold. Their mean price target is less than the 52-week high, but the highest target is up at $10. That would be a gain of more than 74% for the shares. (Wall Street expects two AI stocks to return at least 50% in 2024.)

Guardforce AI

Security solutions and advanced robotics AI.

This Singapore-based provider of integrated security solutions offers a range of security solutions that enhance safety and protection, including cash-handling security solutions, advanced robotics AI, and information security consulting. Its cash-handling services include cash-in-transit, vehicles to banks, ATM management, cash center operations, cash processing, coin processing, consolidating cash center, and cheque center services, as well as cash deposit machine solutions, such as cash deposit management and express cash services. The company also sells and rents robots. Its customers include local commercial banks, chain retailers, coin-manufacturing mints, and government authorities.

The announcement of a new three-year contract with a leading Japanese retailer last fall did nothing for a stock in retreat. Shares began this year in freefall but turned around when the company named a new chief financial officer back in January. Shares were changing hands for a 52-week low of $2.04 then, but the stock is up around 58% since. The consensus recommendation of analysts is to buy shares.

Past-Year Price Change	Target Price	Est. One-Year Gain
−20.3%	$14.00	307.0%

Microbot Medical

Robotics-assisted medical technologies provider.

This pre-clinical medical device company engages in the research, design, development, and commercialization of micro-robotics-assisted medical technologies. Its ViRob platform technology is an autonomous crawling micro-robot that users can control remotely or within the body. Its Self-Cleaning Shunt is a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and normal pressure hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract.

The company reported successful study results back at the end of December, and it named a new chief medical officer last November. The share price briefly jumped after the study results, but the stock is down more than 12% in the past six months to a little more than $1 per share.

Past-Year Price Change	Target Price	Est. One-Year Gain
−50.4%	$8.00	595.7%

The two analysts who follow the stock recommend buying shares, and their consensus price target indicates that they see plenty of upside potential for the coming year.

About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.